Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation:: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis

被引:141
作者
Gutierrez, N. C.
Castellanos, M. V.
Martin, M. L.
Mateos, M. V.
Hernandez, J. M.
Fernandez, M.
Carrera, D.
Rosinol, L.
Ribera, J. M.
Ojanguren, J. M.
Palomera, L.
Gardella, S.
Escoda, L.
Hernandez-Boluda, J. C.
Bello, J. L.
de la Rubia, J.
Lahuerta, J. J.
San Miguel, J. F.
机构
[1] Hosp Univ Salamanca, Hematol Serv, Salamanca 37007, Spain
[2] Univ Salamanca, CSIC, Ctr Invest Canc, E-37008 Salamanca, Spain
[3] Hosp 12 Octubre, E-28041 Madrid, Spain
[4] Univ Oviedo, Hosp Cent Asturias, E-33080 Oviedo, Spain
[5] Univ Barcelona, Hosp Clin Barcelona, IDIBAPS, Barcelona, Spain
[6] Hosp Germans Trias & Pujol, Badalona, Spain
[7] Hosp Galdakao, Bilbao, Spain
[8] Hosp Clin, Zaragoza, Spain
[9] Hosp Dr Josep Trueta, Girona, Spain
[10] Hosp Joan 23, Tarragona, Spain
[11] Univ Valencia, Hosp Clin, Valencia, Spain
[12] Hosp Univ, Santiago De Compostela, Spain
[13] Univ Valencia, Hosp La Fe, Valencia, Spain
关键词
multiple myeloma; genetic abnormalities; FISH; RB deletion;
D O I
10.1038/sj.leu.2404413
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Fluorescence in situ hybridization ( FISH) has become a powerful technique for prognostic assessment in multiple myeloma ( MM). However, the existence of associations between cytogenetic abnormalities compels us to re-assess the value of each abnormality. A total of 260 patients with MM at the time of diagnosis, enrolled in the GEM-2000 Spanish transplant protocol, have been analyzed by FISH in order to ascertain the independent influence on myeloma prognosis of IGH translocations, as well as RB and P53 deletions. Survival analyses showed that patients with t( 4; 14), RB or P53 deletions had a significantly shorter survival than patients without these abnormalities. However, patients with RB deletions without other abnormalities in FISH analysis, displayed a similar outcome to those patients without genetic changes by FISH ( 46 vs 54 months, P = 0.3). In the multivariate analysis the presence of t( 4; 14), RB deletion associated with other abnormalities, age 460 years, high proportion of S-phase cells and advanced stage of the disease according to the International Staging System retained their independent prognostic influence. In summary, RB deletion as a sole abnormality does not lead to a shortening in the survival of MM patients, whereas t( 4; 14) confers the worst prognosis in MM patients treated with high-dose chemotherapy.
引用
收藏
页码:143 / 150
页数:8
相关论文
共 30 条
[1]   Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation [J].
Avet-Loiseau, H ;
Facon, T ;
Grosbois, B ;
Magrangeas, F ;
Rapp, MJ ;
Harousseau, JL ;
Minvielle, S ;
Bataille, R .
BLOOD, 2002, 99 (06) :2185-2191
[2]  
Calasanz MJ, 1997, GENE CHROMOSOME CANC, V18, P84, DOI 10.1002/(SICI)1098-2264(199702)18:2<84::AID-GCC2>3.3.CO
[3]  
2-9
[4]   p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation [J].
Chang, H ;
Qi, C ;
Yi, QL ;
Reece, D ;
Stewart, AK .
BLOOD, 2005, 105 (01) :358-360
[5]   Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3 [J].
Chesi, M ;
Nardini, E ;
Brents, LA ;
Schrock, E ;
Ried, T ;
Kuehl, WM ;
Bergsagel, PL .
NATURE GENETICS, 1997, 16 (03) :260-264
[6]   Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma [J].
Chesi, M ;
Bergsagel, PL ;
Shonukan, OO ;
Martelli, ML ;
Brents, LA ;
Chen, T ;
Schröck, E ;
Ried, T ;
Kuehl, VM .
BLOOD, 1998, 91 (12) :4457-4463
[7]  
Desikan R, 2000, BLOOD, V95, P4008
[8]   Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma [J].
Dewald, GW ;
Therneau, T ;
Larson, D ;
Lee, YK ;
Fink, S ;
Smoley, S ;
Paternoster, S ;
Adeyinka, A ;
Ketterling, R ;
Van Dyke, DL ;
Fonseca, R ;
Kyle, R .
BLOOD, 2005, 106 (10) :3553-3558
[9]   Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy [J].
Drach, J ;
Ackermann, J ;
Fritz, E ;
Krömer, E ;
Schuster, R ;
Gisslinger, H ;
DeSantis, M ;
Zojer, N ;
Fiegl, M ;
Roka, S ;
Schuster, J ;
Heinz, R ;
Ludwig, H ;
Huber, H .
BLOOD, 1998, 92 (03) :802-809
[10]   Chromosome 13 abnormalities identified by FISH analysis and serum β2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy [J].
Facon, T ;
Avet-Loiseau, H ;
Guillerm, G ;
Moreau, P ;
Geneviève, F ;
Zandecki, M ;
Laï, JL ;
Leleu, X ;
Jouet, JP ;
Bauters, F ;
Harousseau, JL ;
Bataille, R ;
Mary, JY .
BLOOD, 2001, 97 (06) :1566-1571